NCT06898970 2026-03-17
Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma
University of California, San Francisco
Phase 2 Recruiting
University of California, San Francisco
QuantumLeap Healthcare Collaborative
Herlev and Gentofte Hospital